ConductScience.org, home

Paper40702000

RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting.

Wang Z and 7 others. Cell Death Discov, 2025. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting. Papers, record 40702000. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40702000

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting.
PubMed
Journal
Cell Death Discov
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.99, provisional
iCite
Revised in PubMed
2025-07-28
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang ZZengbinhttps://orcid.org/0000-0003-0793-1361
2Liu JJiayu
3Lai YYiting
4Zhong QQing
5Su QQian
6Wu LLinqinghttps://orcid.org/0000-0002-7603-4763
7Wang ZZhihonghttps://orcid.org/0000-0002-2225-3100
8Fang ZZhutinghttps://orcid.org/0000-0003-3350-2210

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136941989Downregulation of RBM17 enhances cisplatin sensitivity and inhibits cell invasion in human hypopharyngeal cancer cells.Open Med (Wars)2023https://conductscience.org/library/papers/36941989PubMed
235615981Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma.Adv Sci (Weinh)2022https://conductscience.org/library/papers/35615981PubMed
337575948Proteomics of adjacent-to-tumor samples uncovers clinically relevant biological events in hepatocellular carcinoma.Natl Sci Rev2023https://conductscience.org/library/papers/37575948PubMed
435679518In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies.Cancer Immunol Res2022https://conductscience.org/library/papers/35679518PubMed
537804830Arginine reprograms metabolism in liver cancer via RBM39.Cell2023https://conductscience.org/library/papers/37804830PubMed
635490918RNA binding protein RALY activates the cholesterol synthesis pathway through an MTA1 splicing switch in hepatocellular carcinoma.Cancer Lett2022https://conductscience.org/library/papers/35490918PubMed
735292350Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.J Hepatol2022https://conductscience.org/library/papers/35292350PubMed
837772582RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.Anticancer Res2023https://conductscience.org/library/papers/37772582PubMed
937067402A systems biology-based approach to screen key splicing factors in hepatocellular carcinoma.Mol Carcinog2023https://conductscience.org/library/papers/37067402PubMed
1037726886Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.Cell Adh Migr2023https://conductscience.org/library/papers/37726886PubMed
1137813165An intricate rewiring of cancer metabolism via alternative splicing.Biochem Pharmacol2023https://conductscience.org/library/papers/37813165PubMed
1233794886Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma.Cancer Cell Int2021https://conductscience.org/library/papers/33794886PubMed
1337715846Understanding the role of radiologists in complex treatment decisions for patients with hepatocellular carcinoma.Abdom Radiol (NY)2023https://conductscience.org/library/papers/37715846PubMed
1437597404Alternative splicing events and function in the tumor microenvironment: New opportunities and challenges.Int Immunopharmacol2023https://conductscience.org/library/papers/37597404PubMed
1532497093Exploration of the effects of the CYCLOPS gene RBM17 in hepatocellular carcinoma.PLoS One2020https://conductscience.org/library/papers/32497093PubMed
1634171309Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.Cell2021https://conductscience.org/library/papers/34171309PubMed
1739802808PPARα suppresses growth of hepatocellular carcinoma in a high-fat diet context by reducing neutrophil extracellular trap release.JHEP Rep2025https://conductscience.org/library/papers/39802808PubMed
1836520054AKT1 phosphorylates RBM17 to promote Sox2 transcription by modulating alternative splicing of FOXM1 to enhance cancer stem cell properties in colorectal cancer cells.FASEB J2023https://conductscience.org/library/papers/36520054PubMed
1929018272Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.Nat Rev Gastroenterol Hepatol2018https://conductscience.org/library/papers/29018272PubMed
2034764464Immunotherapies for hepatocellular carcinoma.Nat Rev Clin Oncol2022https://conductscience.org/library/papers/34764464PubMed

See all 35 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42623381Streptomyces-linked exercise gene networks orchestrate immune exclusion and determine immunotherapy response in hepatocellular carcinoma.PLoS One2026https://conductscience.org/library/papers/42623381PubMed
42620997AI-integrated single-cell multi-omics decodes the hepatocellular carcinoma metabolism-immune axis: a new strategy for precision therapeutic targeting.Front Oncol2026https://conductscience.org/library/papers/42620997PubMed
42292467Study of JCAD for prognosis and immune infiltration in hepatocellular carcinoma.Front Immunol2026https://conductscience.org/library/papers/42292467PubMed
42062247RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation.Cell Death Discov2026https://conductscience.org/library/papers/42062247PubMed
41986071
Non-enzymatic Rnaseh2c orchestrates proliferating macrophage-driven immunosuppression and HCC progression via Cdk9 proliferation axis and CCL2/CCR2-mediated CD8+ Tex infiltration: a novel therapeutic paradigm with "Rnaseh2c-In1" inhibitor.
J Immunother Cancer2026https://conductscience.org/library/papers/41986071PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CSAD51380PubTator's text mininghttps://conductscience.org/library/genes/51380NCBI Gene
HACD351495PubTator's text mininghttps://conductscience.org/library/genes/51495NCBI Gene
RBM1784991PubTator's text mininghttps://conductscience.org/library/genes/84991NCBI Gene
RUNX1861PubTator's text mininghttps://conductscience.org/library/genes/861NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40702000

GET https://conductscience.org/api/papers/v1/40702000/references?page=2